BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31914437)

  • 1. One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study.
    Pak KY; Shin JP; Kim HW; Sagong M; Kim YC; Lee SJ; Chung IY; Park SW; Lee JE
    Ophthalmologica; 2020; 243(4):255-262. PubMed ID: 31914437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
    Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
    Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes.
    Mieno H; Yoneda K; Terao N; Yoshii K; Kojima K; Nagata K; Sotozono C
    Korean J Ophthalmol; 2020 Aug; 34(4):290-296. PubMed ID: 32783421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
    Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
    Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
    Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
    Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy.
    Statler B; Conti TF; Conti FF; Silva FQ; Rachitskaya A; Yuan A; Schachat A; Kaiser PK; Singh RP; Babiuch A
    Ophthalmic Surg Lasers Imaging Retina; 2020 Aug; 51(8):448-455. PubMed ID: 32818277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
    Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
    Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial.
    Hirano T; Toriyama Y; Takamura Y; Sugimoto M; Nagaoka T; Sugiura Y; Okamoto F; Saito M; Noda K; Yoshida S; Ishibazawa A; Sawada O; Murata T
    Jpn J Ophthalmol; 2021 May; 65(3):354-362. PubMed ID: 33559843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
    Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
    Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
    Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema.
    Kim YC; Shin JP; Pak KY; Kim HW; Sagong M; Lee SJ; Chung IY; Park SW; Lee JE
    Sci Rep; 2020 Dec; 10(1):22030. PubMed ID: 33328488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
    Campos A; Campos EJ; do Carmo A; Patrício M; Castro de Sousa JP; Ambrósio AF; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema.
    Pichi F; Abdi A; Aljneibi S; El Ghrably I; Agarwal A; Ghazi NG
    Int Ophthalmol; 2024 Jun; 44(1):275. PubMed ID: 38916818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.